Polarean Imaging gets first order for 'Xenoview'.


Medical imaging technology company Polarean Imaging announced on Wednesday that it has received its first order for a gas-blend cylinder for the production of ‘Xenoview’, or xenon Xe 129 hyperpolarised, from Cincinnati Children's Hospital Medical Center.

  • Polarean Imaging
  • 26 April 2023 13:26:27
Polarean Imaging

Source: Sharecast

The AIM-traded firm said Xenoview is the only hyperpolarised contrast agent approved by the US Food and Drug Administration (FDA) for use with magnetic resonance imaging (MRI), for the evaluation of lung ventilation in both adults and paediatric patients aged 12 years and older.

It said the cylinder was expected to provide adequate doses for over 100 patient scans.

Cincinnati Children's, which conducted much of the pioneering research in adolescent children, planned to begin scanning hospital clinic patients in May.

“Since receiving FDA approval at the end of 2022, we have been working diligently to clear the path for commercial distribution of our proprietary gas blend to sites that already have Xenon MRI infrastructure,” said chief executive officer Richard Hullihen.

“We are delighted to secure our first sale of a cylinder and cartons of dose delivery bags for clinical use as we continue to execute our commercial plan.”

At 1307 BST, shares in Polarean Imaging were down 1.43% at 24.15p.

Reporting by Josh White for Sharecast.com.


N/A

ISIN: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Created with Highcharts 11.0.12017201820192020202120222023202420254k6k8k10k12k14k

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.